These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29100350)

  • 1. Prognostic value of chemotherapy in addition to concurrent chemoradiotherapy in T3-4N0-1 nasopharyngeal carcinoma: a propensity score matching study.
    Wu LR; Yu HL; Jiang N; Jiang XS; Zong D; Wen J; Huang L; Xie P; Chen W; Wang TT; Gu DY; Yan PW; Yin L; He X
    Oncotarget; 2017 Sep; 8(44):76807-76815. PubMed ID: 29100350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis.
    Zhong Q; Luo D; Li X; Du Q; Liang Q; Liu W; Li J; Zhu X
    Cancer Biol Ther; 2023 Dec; 24(1):2274121. PubMed ID: 37965924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in Lymph-Node-Stage III nasopharyngeal carcinoma based on propensity score-matching.
    Liu ZC; Zeng KH; Gu ZB; Chen RP; Luo YJ; Tang LQ; Zhu KB; Liu Y; Sun XS; Zeng L
    Radiother Oncol; 2023 Jan; 178():109421. PubMed ID: 36410548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
    Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
    Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
    Wu LR; Jiang XS; Song X; Yu HL; Fan YX; Wang FJ; Huang SF; Guo WJ; He X; Liu JY
    Oncotarget; 2017 Oct; 8(45):79953-79963. PubMed ID: 29108377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Concurrent Chemoradiotherapy Combined With Induction Chemotherapy or Adjuvant Chemotherapy in Patients With Stage II-IVA Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis and Meta-Analysis.
    Yang J; Liang ZG; Jiang YT; Chen KH; Li L; Qu S; Zhu XD
    Front Oncol; 2021; 11():778836. PubMed ID: 34926289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
    Tang SQ; Xu C; Wang XS; Tang LL; Li WF; Chen L; Mao YP; Guo R; Liu Q; Sun Y; Ma J
    Oral Oncol; 2020 Jun; 105():104686. PubMed ID: 32283514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Xu C; Sun R; Tang LL; Chen L; Li WF; Mao YP; Zhou GQ; Guo R; Lin AH; Sun Y; Ma J; Hu WH
    Oral Oncol; 2018 Mar; 78():37-45. PubMed ID: 29496056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
    Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
    Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction Chemotherapy Has No Prognostic Value in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Chronic Hepatitis B Infection in the IMRT Era.
    Zhang LL; Zhou GQ; Li YC; Lin AH; Ma J; Qi ZY; Sun Y
    Transl Oncol; 2017 Oct; 10(5):800-805. PubMed ID: 28844018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era.
    Su Z; Zou GR; Tang J; Li XY; Xie FY
    Ther Clin Risk Manag; 2020; 16():201-211. PubMed ID: 32280230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
    Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
    Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
    Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
    Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of neoadjuvant chemotherapy followed by concurrent chemoradiotherapy (CCRT) vs CCRT alone for nasopharyngeal carcinoma in the era of intensity-modulated radiation therapy using propensity score matching method.
    Chen X; Zhu X; Liang Z; Li L; Qu S; Chen K; Pan X
    Onco Targets Ther; 2017; 10():2909-2921. PubMed ID: 28652773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model.
    Liu W; Yu B; Luo Y; Li J; Yuan X; Wu S; Liang B; Lv Z; Li Y; Peng X; Lu J; Peng X; Liu X
    BMC Cancer; 2021 May; 21(1):639. PubMed ID: 34051750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Explore the Value of Adding Induction Chemotherapy to Concurrent Chemoradiotherapy in T3-4N0M0 Nasopharyngeal Carcinoma Patients: A Retrospective Study.
    Li P; Zhang Q; Luo D; Jiang F; Jin Q; Hua Y; Jin T; Chen X
    Cancer Manag Res; 2021; 13():7067-7076. PubMed ID: 34526821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk N Stage : A Multicenter Retrospective Study From Nonendemic Region of China.
    Zang J; Li Y; Liu Q; Zhu Y; Luo S; Li X; Wang J; Hou B; Su N; Zhao L; Shi M
    Am J Clin Oncol; 2023 May; 46(5):206-212. PubMed ID: 36879390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.